1. Home
  2. UNCY
  3. UNCY Forecast

as 07-12-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.

More About Our UNCY ML Model...

What kind of parameters do you use to train UNCY stocks ML model?

To train our stocks UNCY ML model, we use historical data with over 25 parameters, including volume indicators, volatility indicators, momentum indicators, trend indicators, and other metrics.

How often do you update UNCY ML model?

We update our ML model either weekly or biweekly, depending on the market capitalization of the stocks, using TensorFlow, typically over the weekend.

Why is the accuracy of your UNCY model low?

Unfortunately, our current data provider offers limited historical data, which impacts the accuracy of our ML model. However, as we continue to gather more data over time and add more indicators, we expect the accuracy of our model to improve.

How can I provide and share more data with you to increase your ML model accuracy?

We would greatly appreciate your contribution. Please send an email to [email protected]

Do you offer an ML model for shorter time periods, such as 5 minutes or 15 minutes?

Yes, we offer it for strategy purposes only, with intervals: 1 minute, 2 minutes, 5 minutes, 15 minutes, and 30 minutes etc.

Can I rely on your ML model to make financial decisions regarding buying or selling stocks, or is it only intended for learning purposes?

Our ML model is primarily designed for educational purposes and is not intended to provide financial advice. We strongly recommend consulting with a financial advisor before making any buying or selling decisions.

Share on Social Networks: